IXICO plc (IXI) AI Stock Analysis

• Market Cap: £8.57M
• Dividend Yield: N/A
• Average Volume (3M): 32.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: -13.49%
• EPS Growth: -69.67%
• Country: UK
• Employees: 81
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 92,668,594
• 10 Day Avg. Volume: 25,269
• 30 Day Avg. Volume: 32,734
• PEG Ratio: 0.04
• Price to Book (P/B): 0.50
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

IXICO plc's overall stock score reflects ongoing financial and operational challenges, particularly with declining revenues and profitability issues. However, strategic expansions and new contract wins provide potential future growth, offsetting some negative aspects.

IXICO plc Business Overview & Revenue Model

Company Description

IXICO plc (IXI) is a UK-based company specializing in the provision of data analytics and technology-enabled services primarily to the pharmaceutical and biotechnology industries. The company's core offerings include advanced imaging and digital biomarker analysis solutions, which aid in the clinical development of new therapies, particularly in the field of neurological disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

How the Company Makes Money

IXICO plc generates revenue by offering its specialized data analytics and digital biomarker solutions to pharmaceutical and biotechnology companies engaged in clinical trials. Key revenue streams include service contracts for imaging data analysis, digital biomarker development, and consultation services. The company leverages its proprietary technology platform to provide these services, thereby supporting drug development processes. Additionally, IXICO may enter into strategic partnerships with clinical research organizations and pharmaceutical firms, which can contribute to its earnings through collaborative projects and long-term service agreements.

IXICO plc Financial Statement Overview

Summary

IXICO plc is experiencing financial challenges, particularly in revenue generation and profitability. The decline in revenue growth and negative profit margins suggest operational difficulties. While the balance sheet remains strong with a high equity ratio, the cash flow position is concerning due to negative free cash flow and operational cash constraints. These factors reflect a need for strategic improvements to enhance profitability and cash flow generation.

Income Statement

The company has experienced a significant decline in revenue over the past year, with a negative revenue growth rate of 13.48% from 2023 to 2024. Both EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies. The net profit margin is also negative, reflecting ongoing struggles to achieve profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 84.57%, indicating financial stability. However, the debt-to-equity ratio is low at 0.03, suggesting limited leverage which could restrict growth opportunities. Return on Equity is negative, further highlighting profitability issues.

Cash Flow

The company has faced a substantial decline in free cash flow, dropping from -1.66 million in 2023 to -2.20 million in 2024. The operating cash flow to net income ratio is negative, indicating cash flow difficulties. Additionally, the free cash flow to net income ratio suggests challenges in converting earnings to cash.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
6.00M	5.77M	6.67M	8.64M	9.19M	9.53M
	Gross Profit
2.59M	2.71M	3.27M	4.77M	5.53M	5.91M
	EBIT
-2.32M	-2.15M	-1.44M	111.00K	698.00K	236.00K
	EBITDA
-1.49M	-1.59M	-707.00K	750.00K	1.31M	674.00K
	Net Income Common Stockholders
-1.87M	-2.00M	-1.18M	1.03M	1.51M	952.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.45M	1.79M	4.03M	5.77M	6.68M	7.95M
	Total Assets
10.13M	11.19M	12.99M	14.65M	14.26M	12.10M
	Total Debt
0.00	314.00K	387.00K	516.00K	597.00K	213.00K
	Net Debt
-7.45M	-1.47M	-3.64M	-5.25M	-6.09M	-7.73M
	Total Liabilities
2.55M	1.72M	1.56M	2.16M	2.78M	2.98M
	Stockholders Equity
7.58M	9.46M	11.43M	12.49M	11.48M	9.12M
Cash Flow		Free Cash Flow
-2.05M	-2.20M	-1.66M	-815.00K	-1.54M	795.00K
	Operating Cash Flow
-982.00K	-1.73M	302.00K	1.43M	614.00K	1.94M
	Investing Cash Flow
-1.36M	-377.00K	-1.86M	-2.25M	-2.15M	-1.14M
	Financing Cash Flow
-209.00K	-134.00K	-156.00K	-114.00K	270.00K	-112.00K

IXICO plc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.25
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Positive. The current price of 9.25 is above the 20-day moving average (MA) of 8.94, above the 50-day MA of 8.87, and below the 200-day MA of 9.91, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 57.85 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:IXI.

IXICO plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	53 Neutral	£8.57M	―	-19.15%	―	-13.49%	-69.67%
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%
APTA	49 Neutral	£6.77M	―	-99.43%	―	17.39%	96.02%
OBD	44 Neutral	£7.83M	―	-222.16%	―	24.71%	38.28%
FAB	44 Neutral	£6.93M	―	-129.49%	―	14.12%	78.16%

IXICO plc Corporate Events

IXICO Announces Change in Investment Manager for Major Shareholder

IXICO plc announced a change in the investment manager for Amati AIM VCT plc to Maven Capital Partners UK LLP, resulting in a name change to Maven Renovar VCT plc. Despite this change, there has been no alteration in the position held in IXICO, indicating stability in the company’s shareholder structure. This announcement reflects IXICO’s ongoing commitment to maintaining its operational stability and shareholder confidence, crucial for its strategic positioning in the neuroscience research industry.

Spark’s Take on GB:IXI Stock

According to Spark, TipRanks’ AI Analyst, GB:IXI is a Neutral.

IXICO plc’s overall score reflects financial and operational challenges with declining revenues and profitability issues. However, recent corporate events indicate potential for future growth through strategic expansions and new contracts. Technical indicators and valuation metrics are currently unfavorable, impacting the stock’s attractiveness.

To see Spark’s full report on GB:IXI stock, click here.

IXICO plc to Announce Interim Results and Host Investor Presentation

IXICO plc announced it will release its unaudited interim results for the six months ending 31 March 2025 on 20 May 2025. The company will host a live presentation for shareholders to discuss these results and its ongoing strategy. This event underscores IXICO’s commitment to transparency and engagement with its stakeholders, reinforcing its position as a leader in the neuroscience imaging industry.

Spark’s Take on GB:IXI Stock

According to Spark, TipRanks’ AI Analyst, GB:IXI is a Neutral.

IXICO plc’s overall score reflects financial and operational challenges with declining revenues and profitability issues. However, recent corporate events indicate potential for future growth through strategic expansions and new contracts. Technical indicators and valuation metrics are currently unfavorable, impacting the stock’s attractiveness.

To see Spark’s full report on GB:IXI stock, click here.

IXICO plc Reports Strong First Half 2025 Performance and Strategic Expansion

IXICO plc reported a 26% increase in revenues for the first half of 2025, reaching £3.2 million, and a strong cash balance of £5.0 million. The company has expanded its operations in the US and is enhancing its imaging biomarker analysis for Alzheimer’s and Parkinson’s diseases. This strategic focus is expected to lead to further contract wins in these areas, with increased investment anticipated to boost revenues in 2026 and beyond.

Spark’s Take on GB:IXI Stock

According to Spark, TipRanks’ AI Analyst, GB:IXI is a Neutral.

IXICO plc’s stock is currently under pressure due to financial struggles and negative technical indicators. While new contracts in the imaging sector offer future revenue opportunities, the current financial position and market sentiment present significant challenges.

To see Spark’s full report on GB:IXI stock, click here.

IXICO Secures New Contracts in Alzheimer’s and Huntington’s Disease Imaging

IXICO plc announced the signing of a new commercial contract for Alzheimer’s Disease imaging analysis with a leading biotechnology company and an additional project in Huntington’s Disease with an existing partner. The contracts, valued at over £0.5 million, will be recognized within a year and contribute to IXICO’s ‘Innovate, Lead, Scale’ strategy, potentially leading to further revenues. These agreements highlight IXICO’s status as a global neuroimaging market leader with a strong biomarker technology advantage.